Frequency of Administration of Erythropoiesis-Stimulating Agents for the Anaemia of End-Stage Kidney Disease in Dialysis

被引：0
|
作者：
Webster, Angela
机构：
来源：
NEPHROLOGY | 2015年 / 20卷 / 09期
关键词：
D O I：
10.1111/nep.12438
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：663 / 665
页数：3
相关论文
共 50 条
  • [21] Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
    Vicente Escudero-Vilaplana
    Concepción Martínez-Nieto
    Juan Manuel López-Gómez
    Almudena Vega-Martínez
    José María Bellón-Cano
    María Sanjurjo-Sáez
    International Journal of Clinical Pharmacy, 2013, 35 : 463 - 468
  • [22] Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
    Escudero-Vilaplana, Vicente
    Martinez-Nieto, Concepcion
    Manuel Lopez-Gomez, Juan
    Vega-Martinez, Almudena
    Maria Bellon-Cano, Jose
    Sanjurjo-Saez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (03) : 463 - 468
  • [23] Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients
    Cody, J
    Daly, C
    Campbell, M
    Donaldson, C
    Khan, I
    Vale, L
    Wallace, S
    MacLeod, A
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03):
  • [24] Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients
    Michio Kuwahara
    Youhei Arai
    Eriko Takehara
    Yasunori Sasaki
    Tomoharu Yoshimine
    Keita Kusaka
    Satomi Shikuma
    Wataru Akita
    Shinichi Uchida
    Clinical and Experimental Nephrology, 2016, 20 : 585 - 594
  • [25] Body composition affects the response to erythropoiesis-stimulating agents in patients with chronic kidney disease in dialysis
    Vega, Almudena
    Ruiz, Caridad
    Abad, Soraya
    Quiroga, Borja
    Velazquez, Kyra
    Yuste, Claudia
    Aragoncillo, Ines
    Lopez Gomez, Juan Manuel
    RENAL FAILURE, 2014, 36 (07) : 1073 - 1077
  • [26] Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients
    Kuwahara, Michio
    Arai, Youhei
    Takehara, Eriko
    Sasaki, Yasunori
    Yoshimine, Tomoharu
    Kusaka, Keita
    Shikuma, Satomi
    Akita, Wataru
    Uchida, Shinichi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (04) : 585 - 594
  • [27] Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease
    Carrero, Juan Jesus
    Barany, Peter
    Yilmaz, Mahmut Ilker
    Qureshi, Abdul Rashid
    Sonmez, Alper
    Heimburger, Olof
    Ozgurtas, Tanez
    Yenicesu, Mujdat
    Lindholm, Bengt
    Stenvinkel, Peter
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (02) : 709 - 715
  • [28] An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease
    Del Vecchio, Lucia
    Locatelli, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1021 - 1030
  • [29] End of an era for erythropoiesis-stimulating agents in oncology
    Schoen, Martin W.
    Hoque, Shamia
    Witherspoon, Bartlett J.
    Schooley, Benjamin
    Sartor, Oliver
    Yang, Y. Tony
    Yarnold, Paul R.
    Knopf, Kevin B.
    Hrushesky, William J. M.
    Dickson, Michael
    Chen, Brian J.
    Nabhan, Chadi
    Bennett, Charles L.
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (10) : 2829 - 2835
  • [30] Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence?
    Roger, S. D.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (09) : 1413 - 1422
12345